Join
Live feed
·
PRReleasevia Quantisnow
Jade Biosciences Inc. logo

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

ByQuantisnow·Wall Street's wire, on your screen.
JBIO· Jade Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JBIO (Jade Biosciences Inc.) and more on Quantisnow.